Pharming (PHAR) Gains from Sales and Divestitures (2024 - 2025)
Pharming's (PHAR) quarterly Gains from Sales and Divestitures came in at -$3.7 million in Q4 2025, down 17068.18% YoY from N/an in Q4 2024, and down 17068.18% on a QoQ basis from $22000.0 in Q4 2024.
Pharming (PHAR) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends
Pharming (PHAR) has 2 years of Gains from Sales and Divestitures data on file, last reported at -$3.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.73 Mn |
| Dec 31, 2025 | -3.73 Mn |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |